Notes of Decisions
Cited in
107
cases (
35 in the last 5 years), 2007–2026 · leading case:
Aqua Prods., Inc. v. Matal, 872 F.3d 1290 (Fed. Cir. 2017).
Synopsys, Inc. v. Mentor Graphics Corp., 814 F.3d 1309 (Fed. Cir. 2016).
· cites it 10× “” 35 U.S.C. § 318 (a). 3 The decision of the Board to institute inter partes re- view cannot be appealed.”
SAS Inst. Inc. v. Iancu, 138 S. Ct. 1348 (2018).
· cites it 3× “” 35 U. S. C. §318 (a) (emphasis added). In this context, as in so many others, “any” means “every.”
Sas Inst., Inc. v. Complementsoft, LLC., 825 F.3d 1341 (Fed. Cir. 2016).
· cites it 4× “19 dress every patent claim challenged in an IPR petition?5 The petitioner argued, as does SAS, that the text of the final written decision statutory subsection, 35 U.S.C. § 318 (a), compels the Board to address every petition- challenged claim.”
In Re Cuozzo Speed Tech., LLC, 793 F.3d 1268 (Fed. Cir. 2015).
· cites it 4× “It simply author- izes the Board to issue “a final written decision with respect to the patentability of any patent claim challenged by the petitioner and any new claim added under section 316(d).”
Credit Acceptance Corp. v. Westlake Servs., 859 F.3d 1044 (Fed. Cir. 2017).
· cites it 2× “The court also explained that 35 U.S.C. § 318 (a) (which is identical in all relevant aspects to § 328(a)) “only requires the Board to address claims as to which review was granted” in a final written decision.”
Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019).
· cites it 2× “See 35 U.S.C. § 318 (a). The government itself has recognized that there is a “functional resemblance between inter partes review and litigation,” and that the Board uses “trial-type procedures in inter partes review.”
Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345 (Fed. Cir. 2018).
· cites it 4× “A further conflict arises in the PTAB’s issuance of this “final decision,” for final decision on inter partes review, as authorized by 35 U.S.C. § 318 , applies upon PTAB trial of patentability, a trial that cannot occur when trial is not “instituted.”
Ethicon Endo-Surgery, Inc. v. Covidien Lp, 812 F.3d 1023 (Fed. Cir. 2016).
· cites it 2× “See 35 U.S.C. § 318 (requiring that “the Patent Trial and Appeal Board shall issue a final written deci- sion with respect to the patentability of any patent claim challenged by the petitioner”).”
Fresenius Usa, Inc. v. Baxter Int'l, Inc., 582 F.3d 1288 (Fed. Cir. 2009).
· cites it 2× “With respect to inter partes reexamination, 35 U.S.C. §318 commits the grant of a stay to the district court’s discretion with special heed to the concerns of the patentee: Once an order for inter partes reexamination of a patent has been issued under section 313, the patent…”
Procter & Gamble Co. v. Kraft Foods Global, Inc., 549 F.3d 842 (Fed. Cir. 2008).
· cites it 2× “STAY At the outset, P & G argues that the district court’s stay order violated 35 U.S.C. § 318 . Section 318 reads: Once an order for inter partes reexamination of a patent has been issued under section 313, the patent owner may obtain a stay of any pending litigation which…”
United States v. Arthrex, Inc., 594 U.S. 1 (2021).
“See 35 U. S. C. §318 (b). The Government and Smith & Nephew also note that early Patent Acts authorized the Secretary of State to ap- point two types of officials who made final decisions on questions of patent law.”
— 35 U.S.C. § 318(a) — 1 case
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.